Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Non-Current Assets (2016 - 2025)

Historic Non-Current Assets for Myriad Genetics (MYGN) over the last 16 years, with Q3 2025 value amounting to $383.3 million.

  • Myriad Genetics' Non-Current Assets fell 5136.4% to $383.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 billion, marking a year-over-year decrease of 3122.08%. This contributed to the annual value of $729.6 million for FY2024, which is 1240.24% down from last year.
  • Myriad Genetics' Non-Current Assets amounted to $383.3 million in Q3 2025, which was down 5136.4% from $393.0 million recorded in Q2 2025.
  • In the past 5 years, Myriad Genetics' Non-Current Assets registered a high of $1.0 billion during Q1 2021, and its lowest value of $383.3 million during Q3 2025.
  • For the 5-year period, Myriad Genetics' Non-Current Assets averaged around $794.8 million, with its median value being $832.9 million (2023).
  • Per our database at Business Quant, Myriad Genetics' Non-Current Assets surged by 1055.15% in 2022 and then tumbled by 5136.4% in 2025.
  • Myriad Genetics' Non-Current Assets (Quarter) stood at $835.9 million in 2021, then grew by 10.55% to $924.1 million in 2022, then dropped by 9.87% to $832.9 million in 2023, then fell by 12.4% to $729.6 million in 2024, then tumbled by 47.46% to $383.3 million in 2025.
  • Its Non-Current Assets was $383.3 million in Q3 2025, compared to $393.0 million in Q2 2025 and $718.9 million in Q1 2025.